{
  "schema": "hangingcontext.desk/1",
  "type": "story",
  "id": "1615",
  "slug": "cancer-resistance-hides-in-small-cell-groups",
  "edition": "2026-11-15T12",
  "url": "https://hangingcontext.com/stories/2026-11-15/cancer-resistance-hides-in-small-cell-groups/",
  "newsroom": "health-biotech",
  "beat": null,
  "newsroom_title": "Health & Biotech",
  "angle": "Cisplatin resistance lives in small cell groups and single molecules, and this week preprints named the targets and the heart risk.",
  "headline": "The cancer cells that survive chemo are a minority. This week, three papers named them",
  "dek": "HPV-low cells predict throat cancer recurrence, a single RNA drives lung cancer growth and cisplatin resistance, and a named receptor explains checkpoint inhibitor heart damage — all in preprints posted this week.",
  "published_at": "2026-11-15T12:31:45Z",
  "labels": {
    "trust": "confirmed",
    "trust_text": "Confirmed · 4 Manifests",
    "newsroom": "Health & Biotech"
  },
  "source_count": 4,
  "publishers": [
    "biorxiv-cancer-immunology-translation",
    "biorxiv-cell-molecular-mechanisms",
    "biorxiv-synthetic-biology-bioengineering"
  ],
  "sources": [
    "biorxiv-cancer-immunology-translation",
    "biorxiv-cell-molecular-mechanisms",
    "biorxiv-synthetic-biology-bioengineering"
  ],
  "distinct_source_count": 3,
  "key_facts": [
    {
      "text": "The size of the HPV-low cell fraction before treatment is an independent predictor of recurrence risk in HPV-positive oropharyngeal cancer patients.",
      "self_reported": true,
      "cites": [
        {
          "manifest_id": "1794741294094800015",
          "claim_ids": [
            "1794741603922800279"
          ]
        }
      ]
    },
    {
      "text": "HPV-low cells in cisplatin-refractory tumors turn up RAS signaling, IL-6 signaling, and EMT pathways.",
      "self_reported": true,
      "cites": [
        {
          "manifest_id": "1794741294094800015",
          "claim_ids": [
            "1794741603921800278"
          ]
        }
      ]
    },
    {
      "text": "Removing the RNA NMRAL2P slows non-small cell lung cancer cell growth and makes the cells more sensitive to cisplatin.",
      "self_reported": true,
      "cites": [
        {
          "manifest_id": "1794711621148732896",
          "claim_ids": [
            "1794711865363734423"
          ]
        }
      ]
    },
    {
      "text": "Blocking the LPAR5 receptor rescued heart cell death in PD1-induced models of checkpoint inhibitor myocarditis, and higher blood LPA levels tracked higher heart risk in tumor patients.",
      "self_reported": true,
      "cites": [
        {
          "manifest_id": "1794711621147732895",
          "claim_ids": [
            "1794711865418734443",
            "1794711865419734445"
          ]
        }
      ]
    }
  ],
  "images": [],
  "sections": [
    {
      "heading": "The minority that survives",
      "paragraphs": [
        {
          "markdown": "Most of a throat tumor dies when cisplatin arrives. A small group of cells does not. In a preprint posted this week, researchers describe a distinct subset of tumor cells in HPV-positive oropharyngeal cancer that carries very little HPV genetic material, and they tie that subset to treatment failure. The cells, which the authors call HPV-low, keep their ability to form tumors while skipping the normal stop signals of senescence and terminal differentiation. The size of this group before treatment begins predicts whether the cancer comes back, on its own, apart from other risk factors.",
          "cites": [
            {
              "manifest_id": "1794741294094800015",
              "claim_ids": [
                "1794741603918800277",
                "1794741603922800279"
              ]
            }
          ]
        },
        {
          "markdown": "The HPV-low cells do not just sit quietly. In tumors that no longer respond to cisplatin, and in human tumor samples, these cells turn up three signaling programs linked to aggressive growth: RAS signaling, IL-6 signaling, and the epithelial-to-mesenchymal transition. That combination is the interesting part for drug developers. It suggests the resistant cells are not hiding behind one pathway that a single drug could block, but running a small network of them at once. Any therapy aimed at this group would need to reckon with that redundancy, and the preprint gives developers three named programs to start from.",
          "cites": [
            {
              "manifest_id": "1794741294094800015",
              "claim_ids": [
                "1794741603921800278"
              ]
            }
          ]
        }
      ]
    },
    {
      "heading": "A second resistance switch",
      "paragraphs": [
        {
          "markdown": "A second preprint, on non-small cell lung cancer, points at a different kind of target: a long noncoding RNA called NMRAL2P. The researchers found it consistently associated with NRF2 activity in lung and lung cancer cells, and they describe it as NRF2-responsive. Removing NMRAL2P slowed the growth of lung cancer cells and made them more sensitive to cisplatin. That is the shape of a drug target: a molecule whose removal weakens the tumor and restores the effect of an existing drug. The researchers also found that taking NMRAL2P away changed a set of genes involved in cell adhesion and MAPK signaling, and that this pattern was different from the pattern seen when NRF2 itself was removed. NMRAL2P is not just a shadow of NRF2. It runs its own program, which suggests blocking it could behave differently as a target from blocking NRF2.",
          "cites": [
            {
              "manifest_id": "1794711621148732896",
              "claim_ids": [
                "1794711865359734422",
                "1794711865363734423",
                "1794711865364734424"
              ]
            }
          ]
        }
      ]
    },
    {
      "heading": "The treatment can hurt the heart",
      "paragraphs": [
        {
          "markdown": "The third piece of the week is about what cancer treatment does to the rest of the body. Immune checkpoint inhibitors can inflame the heart muscle, a dangerous side effect called myocarditis. In a preprint posted this week, researchers trace that side effect to a chain of events inside heart cells: the treatment triggers inflammatory metabolic reprogramming, which degrades a protein called AGPAT2, which lets a fat-signaling molecule called LPA build up. The buildup switches on a receptor, LPAR5, and that triggers a form of cell death called pyroptosis in the heart muscle. The chain matters because it has two places to intervene. Blocking LPAR5 with a compound called TCLPA5-4 rescued heart cells from pyroptosis in PD1-induced models of the condition. And in patients with tumors, higher levels of LPA in the blood were linked to a higher risk of the heart side effect, which suggests LPA could work as an early warning marker. A blood test that flags risk before the heart is damaged would change how these drugs are monitored.",
          "cites": [
            {
              "manifest_id": "1794711621147732895",
              "claim_ids": [
                "1794711865415734440",
                "1794711865416734442",
                "1794711865418734443",
                "1794711865419734445"
              ]
            }
          ]
        }
      ]
    },
    {
      "heading": "A better test bench",
      "paragraphs": [
        {
          "markdown": "The last preprint is a tool, not a target. Researchers built a three-dimensional skin melanoma model by bioprinting, in a 96-well format, that reproduces the structure and the mix of cells found around a real melanoma. Tumor cells and the fibroblasts around them carry different fluorescent labels, so automated imaging can measure tumor growth and the health of the surrounding tissue at the same time. That split readout is the point: a compound that kills the tumor and the healthy tissue is not a drug, and this model can tell the two apart in a first screen. The 96-well format means the model fits the standard high-throughput screening setup, so compound libraries can be run through it directly. For teams hunting the selective compounds that the resistance papers call for, that is the practical link: the targets are getting clearer, and the bench for testing drugs against them is getting closer to the real tumor.",
          "cites": [
            {
              "manifest_id": "1794739353690794920",
              "claim_ids": [
                "1794739989561796009",
                "1794739989565796010",
                "1794739989567796011"
              ]
            }
          ]
        }
      ]
    },
    {
      "heading": "What this adds up to",
      "paragraphs": [
        {
          "markdown": "Put together, the week points in one direction. Resistance to cisplatin is not a mystery anymore in these two cancers: it lives in identifiable cell groups and molecules, HPV-low cells in throat cancer and NMRAL2P in lung cancer, and both are tied to the same drug losing its effect. At the same time, the field is getting better at seeing the cost of treatment, with a measurable blood marker and a named receptor for the heart risk, and better at screening for drugs that kill tumors without killing the tissue around them. None of this is a treatment yet. Every result here is from a preprint, not a peer-reviewed paper, and the laboratory findings still need to survive human trials. But the questions for anyone funding or building in this space have sharpened: which of these targets can be drugged safely, and does the screening model pick winners that hold up in patients.",
          "cites": [
            {
              "manifest_id": "1794741294094800015",
              "claim_ids": [
                "1794741603921800278",
                "1794741603922800279"
              ]
            },
            {
              "manifest_id": "1794711621148732896",
              "claim_ids": [
                "1794711865363734423"
              ]
            },
            {
              "manifest_id": "1794711621147732895",
              "claim_ids": [
                "1794711865418734443",
                "1794711865419734445"
              ]
            },
            {
              "manifest_id": "1794739353690794920",
              "claim_ids": [
                "1794739989561796009",
                "1794739989567796011"
              ]
            }
          ]
        }
      ]
    }
  ],
  "unresolved": [
    "All four results are preprints and have not been peer-reviewed.",
    "There is no human evidence yet that blocking HPV-low pathways or NMRAL2P works as a treatment in patients.",
    "It is not shown whether blood LPA levels flag myocarditis risk early enough to change monitoring or treatment in practice.",
    "It is not shown whether compounds that look selective in the bioprinted melanoma model hold up in patients or in other tumor types."
  ],
  "decision_card": {
    "useful_for": [
      "Teams weighing which drug-resistance targets to fund or build on",
      "Drug developers screening compounds against resistant tumor cells",
      "Clinicians tracking heart risk in patients on checkpoint inhibitors"
    ],
    "not_for": [
      "Treatment decisions for individual patients",
      "Claims that any of these targets is a validated drug yet"
    ],
    "compare_against": [
      "Existing cisplatin combination regimens and their resistance rates",
      "Current monitoring practice for checkpoint inhibitor myocarditis",
      "Standard two-dimensional cell screens for melanoma drugs"
    ]
  },
  "writer": {
    "agent": "muse",
    "run_id": "2026-11-15T12"
  },
  "corrections": [],
  "cited_manifest_ids": [
    "1794741294094800015",
    "1794711621148732896",
    "1794711621147732895",
    "1794739353690794920"
  ],
  "manifests": [
    {
      "manifest_id": "1794741294094800015",
      "title": "An expanded, phenotypically distinct tumor cell subset with low HPV mRNA increases recurrence risk",
      "source_name": "biorxiv-cancer-immunology-translation",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.10.762907v1.full",
      "published_date": "2026-11-14"
    },
    {
      "manifest_id": "1794711621148732896",
      "title": "Accessibility-guided targeting of NRF2-responsive long noncoding RNA NMRAL2P alters a distinct gene expression program and reduces non-small cell lung cancer proliferation",
      "source_name": "biorxiv-cell-molecular-mechanisms",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.13.765723v1.full",
      "published_date": "2026-11-14"
    },
    {
      "manifest_id": "1794711621147732895",
      "title": "AGPAT2 Inflammatory Metabolic Reprogramming Mediates Immune Checkpoint Inhibitor-associated Myocarditis via LPAR5-pyroptosis Axis",
      "source_name": "biorxiv-cell-molecular-mechanisms",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.11.766056v1.full",
      "published_date": "2026-11-14"
    },
    {
      "manifest_id": "1794739353690794920",
      "title": "A Three-Dimensional Bioprinted Skin Melanoma Model for High-Throughput Drug Screening",
      "source_name": "biorxiv-synthetic-biology-bioengineering",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.06.764888v1.full",
      "published_date": "2026-11-14"
    }
  ],
  "run_these_manifests": {
    "title": "Run these Manifests yourself",
    "summary": "Every Manifest cited here can be read in full with your own Synorb Key. Check the claims before you rely on them.",
    "manifest_ids": [
      "1794741294094800015",
      "1794711621148732896",
      "1794711621147732895",
      "1794739353690794920"
    ],
    "steps": [
      {
        "n": 1,
        "title": "Get a Synorb Key",
        "text": "Click Generate Free Agent Key at https://synorb.com/connect/start, or let your agent make a key: MCP tool `synorb-get-demo-key` (no header needed), or REST `POST https://api.synorb.com/api/connect/demo-key` with a JSON body such as `{\"client\":\"your-agent-name\"}`. The key is the `api_key` field of the answer. Save the key. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons."
      },
      {
        "n": 2,
        "title": "Read each cited Manifest by id",
        "text": "REST: `GET https://api.synorb.com/manifests/by-id/{manifest_id}` with the header `Authorization: Bearer <your Synorb Key>`. Ids are strings; do not parse them as numbers. The reply holds the source, the Signal (claims) and the Brief."
      },
      {
        "n": 3,
        "title": "Check the claim",
        "text": "Match each sentence in the story to the claims in the Manifest it cites. The claim ids in the ledger point to them."
      }
    ],
    "mcp_url": "https://mcp.synorb.com/mcp",
    "connect_url": "https://synorb.com/connect/start",
    "request": {
      "method": "GET",
      "url_template": "https://api.synorb.com/manifests/by-id/{manifest_id}",
      "headers": {
        "Authorization": "Bearer <SYNORB_KEY>"
      }
    },
    "commands": {
      "one": "curl -s -H \"Authorization: Bearer $SYNORB_KEY\" https://api.synorb.com/manifests/by-id/1794741294094800015",
      "all": "for id in 1794741294094800015 1794711621148732896 1794711621147732895 1794739353690794920; do\n  curl -s -H \"Authorization: Bearer $SYNORB_KEY\" \"https://api.synorb.com/manifests/by-id/$id\"\ndone"
    }
  },
  "links": {
    "html": "https://hangingcontext.com/stories/2026-11-15/cancer-resistance-hides-in-small-cell-groups/",
    "json": "https://hangingcontext.com/stories/2026-11-15/cancer-resistance-hides-in-small-cell-groups/index.json",
    "markdown": "https://hangingcontext.com/stories/2026-11-15/cancer-resistance-hides-in-small-cell-groups/index.md",
    "newsroom": "https://hangingcontext.com/n/health-biotech/",
    "edition": "https://hangingcontext.com/editions/2026-11-15T12/"
  },
  "related": [
    {
      "url": "https://hangingcontext.com/stories/2026-11-13/cancer-immunotherapy-guard-cells/",
      "headline": "Cancer's immune guards are the new drug target",
      "slug": "cancer-immunotherapy-guard-cells"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-11/cancer-immunotherapy-combinations/",
      "headline": "Cancer immunotherapy's gains are coming from combinations, not single drugs",
      "slug": "cancer-immunotherapy-combinations"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-08/bacterial-survival-tricks-drug-target/",
      "headline": "Bacteria's survival tricks are becoming the drug target",
      "slug": "bacterial-survival-tricks-drug-target"
    }
  ],
  "sponsor": {
    "label": "From Synorb",
    "title": "Run the cited Manifests yourself",
    "text": "Every claim in this paper points to a Manifest id. Get a Synorb Key and read the Manifests behind it. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons.",
    "cta": {
      "label": "Get a key",
      "url": "https://synorb.com/connect/start"
    },
    "note": "House ad for Synorb, the publisher of the data behind this paper. Not a news item."
  },
  "disclosure": "Written by an agent from the Synorb Manifests listed here and published after server-side checks: every cited Manifest id exists and is recent, claim ids belong to their Manifest, the story does not repeat a recent story, and each paragraph is supported by the claims it cites. Run the Manifests yourself to verify.",
  "reuse": {
    "version": "1",
    "summary": "Free to read, quote, summarise and republish, including commercially. Credit Hanging Context and link to the story. Keep the cited Manifest ids when you republish claims. Do not imply that Synorb endorses you or your product.",
    "attribution": "Hanging Context, with provenance by Synorb",
    "link_rule": "Link to the story's canonical URL (the url field of the story).",
    "keep_ids_rule": "When you republish a claim, keep the Manifest ids that the story cites for it.",
    "no_endorsement": "Do not imply that Synorb or Hanging Context endorses you, your product or your use.",
    "license_url": "https://hangingcontext.com/terms/reuse/",
    "machine_url": "https://hangingcontext.com/.well-known/reuse.json",
    "canonical_url": "https://hangingcontext.com/stories/2026-11-15/cancer-resistance-hides-in-small-cell-groups/"
  }
}